Changes in Risk of Immediate Adverse Reactions to Iodinated Contrast Media by Repeated Administrations in Patients with Hepatocellular Carcinoma

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Fujiwara, Naoto ^a   Tateishi, Ryosuke ^a   Akahane, Masaaki ^a   Taguri, Masataka ^b   Minami, Tatsuya ^a   Mikami, Shintaro ^a   Sato, Masaya ^a   Uchino, Kouji ^a   Enooku, Kenichiro ^a   Kondo, Yuji ^a   Asaoka, Yoshinari ^a   Yamashiki, Noriyo ^a   Goto, Tadashi ^a   Shiina, Shuichiro ^a   Yoshida, Haruhiko ^a   Ohtomo, Kuni ^a   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IODINATED CONTRAST MEDIUM; IOHEXOL; IOPAMIDOL;

ADULT; ADVERSE DRUG REACTION; AGED; ALLERGIC REACTION; ANAPHYLAXIS; ARTICLE; BRONCHOSPASM; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCED ULTRASONOGRAPHY; CONTRAST ENHANCEMENT; CONVULSION; COUGHING; DIZZINESS; DYSPNEA; ECHOGRAPHY; FAINTNESS; FEMALE; FLUSHING; GASTROINTESTINAL DISEASE; HEADACHE; HEAT SENSATION; HUMAN; HYPERTENSION; HYPOTENSION; INCIDENCE; KIDNEY DISEASE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRURITUS; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; SNEEZING; TACHYCARDIA; THORAX PAIN; THROAT IRRITATION; UNCONSCIOUSNESS; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; IODINE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; YOUNG ADULT;

EID: 84884860336     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076018     Document Type: Article

References (35)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917. doi:10.1002/ijc.25516. PubMed: 21351269.
2. Bosch FX, Ribes J, Díaz M, Cléries R, (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127: S5-S16. doi:10.1053/j.gastro.2004.05.058. PubMed: 15508102.
3. El-Serag HB, (2011) Hepatocellular carcinoma. N Engl J Med 365: 1118-1127. doi:10.1056/NEJMra1001683. PubMed: 21992124.
4. Mikami S, Tateishi R, Akahane M, Asaoka Y, Kondo Y, et al. (2012) Computed tomography follow-up for the detection of hepatocellular carcinoma recurrence after initial radiofrequency ablation: a single-center experience. J Vasc Interv Radiol 23: 1269-1275. doi:10.1016/j.jvir.2012.06.032. PubMed: 22999746.
5. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, et al. (2012) Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 107: 569-577; quiz: 10.1038/ajg.2011.425. PubMed: 22158026.
6. Caro JJ, Trindade E, McGregor M, (1991) The risks of death and of severe nonfatal reactions with high- vs low-osmolality contrast media: a meta-analysis. AJR Am J Roentgenol 156: 825-832. doi:10.2214/ajr.156.4.1825900. PubMed: 1825900.
7. Wolf GL, Mishkin MM, Roux SG, Halpern EF, Gottlieb J, et al. (1991) Comparison of the rates of adverse drug reactions. Ionic contrast agents, ionic agents combined with steroids, and nonionic agents. Invest Radiol 26: 404-410. doi:10.1097/00004424-199105000-00003. PubMed: 2055736.
8. Hagan JB, (2004) Anaphylactoid and adverse reactions to radiocontrast agents. Immunol Allergy Clin North Am 24: 507-519, vii-viii doi:10.1016/j.iac.2004.03.005. PubMed: 15242724.
9. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, et al. (2004) Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 113: 832-836. doi:10.1016/j.jaci.2003.12.591. PubMed: 15131563.
10. Barrett BJ, Parfrey PS, McDonald JR, Hefferton DM, Reddy ER, et al. (1992) Nonionic low-osmolality versus ionic high-osmolality contrast material for intravenous use in patients perceived to be at high risk: randomized trial. Radiology 183: 105-110. PubMed: 1549654.
11. Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, et al. (1990) Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology 175: 621-628. PubMed: 2343107.
12. Andrew E, Berg KJ, (2004) Nephrotoxic effects of X-ray contrast media. J Toxicol Clin Toxicol 42: 325-332. doi:10.1081/CLT-120037430. PubMed: 15362604.
13. Morcos SK, Thomsen HS, (2001) Adverse reactions to iodinated contrast media. Eur Radiol 11: 1267-1275. doi:10.1007/s003300000729. PubMed: 11471623.
14. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, et al. (2011) The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 80: 17-28. doi:10.1038/ki.2010.483. PubMed: 21150873.
15. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R, (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60: 646-649. doi:10.1002/bjs.1800600817. PubMed: 4541913.
16. Tramèr MR, von Elm E, Loubeyre P, Hauser C, (2006) Pharmacological prevention of serious anaphylactic reactions due to iodinated contrast media: systematic review. BMJ 333: 675. doi:10.1136/bmj.38905.634132.AE. PubMed: 16880193.
17. Lasser EC, Berry CC, Talner LB, Santini LC, Lang EK, et al. (1987) Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med 317: 845-849. doi:10.1056/NEJM198710013171401. PubMed: 3627208.
18. Greenberger PA, Patterson R, Tapio CM, (1985) Prophylaxis against repeated radiocontrast media reactions in 857 cases. Adverse experience with cimetidine and safety of beta-adrenergic antagonists. Arch Intern Med 145: 2197-2200. doi:10.1001/archinte.145.12.2197. PubMed: 2866755.
19. Thomsen HS, Morcos SK, (2006) ESUR guidelines on contrast media. Abdom Imaging 31: 131-140. doi:10.1007/s00261-005-0380-y. PubMed: 16447092.
20. Ichikawa T, Saito K, Yoshioka N, Tanimoto A, Gokan T, et al. (2010) Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 45: 133-141. doi:10.1097/RLI.0b013e3181caea5b. PubMed: 20098330.
21. Hwang J, Kim SH, Lee MW, Lee JY, (2012) Small (
22. Lencioni R, Piscaglia F, Bolondi L, (2008) Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol 48: 848-857. doi:10.1016/j.jhep.2008.02.005. PubMed: 18328590.
23. Sano K, Ichikawa T, Motosugi U, Sou H, Muhi AM, et al. (2011) Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 261: 834-844. doi:10.1148/radiol.11101840. PubMed: 21998047.
24. Khalili K, Kim TK, Jang HJ, Haider MA, Khan L, et al. (2011) Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol 54: 723-728. doi:10.1016/j.jhep.2010.07.025. PubMed: 21156219.
25. American College of Radiology (2012) Adverse Events After Intravascular Iodinated Contrast Media Administration. ACR Manual on Contrast Media version 8. Reston, VA, American: College of Radiology. pp. pp. 21-28.
26. Greenland S, (1995) Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 6: 356-365. doi:10.1097/00001648-199507000-00005. PubMed: 7548341.
27. Agresti A, (2002) Categorical Data Analysis, 2nd ed. New York: Wiley.
28. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, et al. (2005) Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67: 2089-2100. doi:10.1111/j.1523-1755.2005.00365.x. PubMed: 15882252.
29. Davenport MS, Cohan RH, Caoili EM, Ellis JH, (2009) Repeat contrast medium reactions in premedicated patients: frequency and severity. Radiology 253: 372-379. doi:10.1148/radiol.2532090465. PubMed: 19789241.
30. Freed KS, Leder RA, Alexander C, DeLong DM, Kliewer MA, (2001) Breakthrough adverse reactions to low-osmolar contrast media after steroid premedication. AJR Am J Roentgenol 176: 1389-1392. doi:10.2214/ajr.176.6.1761389. PubMed: 11373198.
31. Lang DM, Alpern MB, Visintainer PF, Smith ST, (1991) Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma. Ann Intern Med 115: 270-276. doi:10.7326/0003-4819-115-4-270. PubMed: 1677239.
32. Lang DM, Alpern MB, Visintainer PF, Smith ST, (1993) Elevated risk of anaphylactoid reaction from radiographic contrast media is associated with both beta-blocker exposure and cardiovascular disorders. Arch Intern Med 153: 2033-2040. doi:10.1001/archinte.1993.00410170119012. PubMed: 8102844.
33. Bettmann MA, Heeren T, Greenfield A, Goudey C, (1997) Adverse events with radiographic contrast agents: results of the SCVIR Contrast Agent Registry. Radiology 203: 611-620. PubMed: 9169677.
34. Dahlstrom K, Shaw DD, Clauss W, Andrew E, Sveen K, (1985) Summary of U.S. and European intravascular experience with iohexol based on the clinical trial program. Invest Radiol 20: S117-S121. doi:10.1097/00004424-198501002-00028. PubMed: 3882613.
35. Kopp AF, Mortele KJ, Cho YD, Palkowitsch P, Bettmann MA, et al. (2008) Prevalence of acute reactions to iopromide: postmarketing surveillance study of 74,717 patients. Acta Radiol 49: 902-911. doi:10.1080/02841850802282811. PubMed: 18651252.